Single-Domain SARS-CoV-2 S1 and RBD Antibodies Isolated from Immunized Llama Effectively Bind Targets of the Wuhan, UK, and South African Strains in vitro
Yamane, D.; Lu, I.; Tiahjono, W.; Rubidoux, L.; Hussain, A.; Cancilla, J. C.; Duggan, E.; Shaner, N. C.; Nakanishi, N.; Wang, J.
Show abstract
The spreading of SARS-CoV-2 variants has become a major challenge of the current fight against the pandemic. Of particular concerns are the strains that have arisen from the United Kingdom (UK) and South Africa. The UK variant spreads rapidly and is projected to overtake the original strain in the US as early as in March 2021, while the South African variant appears to evade some effects of the current vaccines. Potential false-negative diagnosis using currently available antigen kits that may not recognize these variants could cause another wave of community infection. Therefore, it is imperative that antibodies used in the detection kits are validated for binding against these variants. Here we report that the nanoantibodies (nAbs in our terminology, also referred to as VHH fragments, single domain antibodies, nanobodies) that we have developed for rapid antigen detection test bind the receptor binding domain (RBD) of the S1 protein from the original COVID-SARS-2 virus as well as those from the UK and South African variants. This finding validates our antibodies used in our assay for the detection of these major variant strains.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjects 94%
- A recombinant gp145 Env glycoprotein from HIV-1 expressed in two different cell lines: effects on glycosylation and antigenicity 93%
- Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform 93%
Similar papers in this journal
- Scalable, Micro-Neutralization Assay for Qualitative Assessment of SARS-CoV-2 (COVID 19) Virus-Neutralizing Antibodies in Human Clinical Samples 93%
- Microarray-based detection of antibodies against SARS-CoV-2 proteins, common respiratory viruses and type I interferons 93%
- A cellular assay for spike/ACE2 fusion: quantification of fusion-inhibitory antibodies after COVID-19 and vaccination 93%
Similar papers in this journal
- SARS-CoV-2 neutralizing camelid heavy-chain-only antibodies as powerful tools for diagnostic and therapeutic applications 94%
- Development of an Escape-resistant SARS CoV-2 Neutralizing Synthetic Nanobody 93%
- In vitro, classical complement activation differs by disease severity and between SARS-CoV-2 antigens 92%
Similar papers in this journal
- Divalent HIV-1 gp120 Immunogen Exhibits Selective Avidity for Broadly Neutralizing Antibody VRC01 Precursors 93%
- Surrogate virus neutralisation test based on nanoluciferase-tagged antigens to quantify inhibitory antibodies against SARS-CoV-2 and characterise Omicron-specific reactivity 93%
- Validation of a novel fluorescent lateral flow assay for rapid qualitative and quantitative assessment of total anti-SARS-CoV-2 S-RBD binding antibody units (BAU) from plasma or fingerstick whole-blood of COVID-19 vaccinees 93%
Similar papers in this journal
- Impact of serum versus anticoagulant-containing plasma on influenza virusneuraminidase-based serological assays 92%
- PERMISSIVE OMICRON BREAKTHROUGH INFECTIONS IN INDIVIDUALS WITH BINDING OR NEUTRALIZING ANTIBODIES TO ANCESTRAL SARS-CoV-2 92%
- The unmutated common ancestor of Gp41 conformational epitope targeting variable heavy chain 1-02 utilizing antibodies maintains antibody dependent cell cytotoxicity 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.